Avhandlingar & publikationer

Här lägger vi publikationer för 2020.

1. Olén O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, Ekbom A, Malmborg P, Ludvigsson JF. Increased Mortality of Patients With Childhood-Onset Inflammatory Bowel Diseases, Compared With the General Population. Gastroenterology. 2019 Feb;156(3):614-622. doi: 10.1053/j.gastro.2018.10.028. Epub 2018 Oct 17. PubMed PMID: 30342031.
2. Everhov ÅH, Sachs MC, Malmborg P, Nordenvall C, Myrelid P, Khalili H, Elmberg M, Ekbom A, Askling J, Jakobsson G, Halfvarson J, Ludvigsson JF, Olén O. Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients. Scand J Gastroenterol. 2019 Jan;54(1):55-63. doi:10.1080/00365521.2018.1564361. Epub 2019 Jan 31. PubMed PMID: 30700170.
3. Ludvigsson JF, Mahl M, Sachs MC, Björk J, Michaelsson K, Ekbom A, Askling J, Backman AS, Olén O. Fracture Risk in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study From 1964 to 2014. Am J Gastroenterol. 2019 Feb;114(2):291-304. doi: 10.14309/ajg.0000000000000062. PubMed PMID: 30730858.
4. Malmborg P, Mouratidou N, Sachs MC, Hammar U, Khalili H, Neovius M, Hjern A, Smedby KE, Ekbom A, Askling J, Ludvigsson JF, Olén O. Effects of Childhood-onset Inflammatory Bowel Disease on School Performance: A Nationwide Population-based Cohort Study Using Swedish Health and Educational Registers. Inflamm Bowel Dis.2019 Sep 18;25(10):1663-1673. doi: 10.1093/ibd/izz040. PubMed PMID: 30916332.
5. Forss A, Myrelid P, Olén O, Everhov ÅH, Nordenvall C, Halfvarson J, Ludvigsson JF. Validating surgical procedure codes for inflammatory bowel disease in the Swedish National Patient Register. BMC Med Inform Decis Mak. 2019 Nov 11;19(1):217. doi: 10.1186/s12911-019-0948-z. PubMed PMID: 31711471; PubMedCentral PMCID: PMC6849315.
6. Ludvigsson JF, Andersson M, Bengtsson J, Eberhardson M, Fagerberg UL, Grip O, Halfvarson J, Hjortswang H, Jäghult S, Karling P, Nordenvall C, Olén O, Olsson M, Rejler M, Strid H, Myrelid P. Swedish Inflammatory Bowel Disease Register (SWIBREG) – a nationwide quality register. Scand J Gastroenterol. 2019 Sep;54(9):1089-1101. doi: 10.1080/00365521.2019.1660799. Epub 2019 Sep 9. PubMed PMID: 31498717.
7. Abdalla M, Norblad R, Olsson M, Landerholm K, Andersson P, Söderholm JD, Andersson R, Myrelid P. Anorectal Function After Ileo-Rectal Anastomosis Is Better than Pelvic Pouch in Selected Ulcerative Colitis Patients. Dig Dis Sci. 2020 Jan;65(1):250-259. doi: 10.1007/s10620-019-05757-6. Epub 2019 Aug 1. PubMed PMID: 31372911; PubMed Central PMCID: PMC6943403.
8. Landerholm K, Kalman D, Wallon C, Myrelid P. Immunomodulators: Friends or Enemies in Surgery for Crohn’s Disease? Curr Drug Targets. 2019;20(13):1384-1398. doi: 10.2174/1389450120666190617163919. PubMed PMID: 31237212.
9. Everhov ÅH, Khalili H, Askling J, Myrelid P, Ludvigsson JF, Halfvarson J, Nordenvall C, Neovius M, Söderling J, Olén O. Work Loss Before and After Diagnosis of Crohn’s Disease. Inflamm Bowel Dis. 2019 Jun 18;25(7):1237-1247. doi: 10.1093/ibd/izy382. PubMed PMID: 30551185.
10. Casado-Bedmar M, Heil SDS, Myrelid P, Söderholm JD, Keita ÅV. Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis. Neurogastroenterol Motil. 2019 Mar;31(3):e13503. doi: 10.1111/nmo.13503. Epub 2018 Nov 8. PubMed PMID: 30407703.
11. Butwicka A, Sariaslan A, Larsson H, Halfvarson J, Myrelid PE, Olén O, Frisen L, Lichtenstein P, Ludvigsson JF. No association between urbanisation, neighbourhood deprivation and IBD: a population-based study of 4 million individuals. Gut. 2019 May;68(5):947-948. doi: 10.1136/gutjnl-2018-316326. Epub2018 Apr 24. PubMed PMID: 29691277.
12. Vessby J, Lampinen M, Åberg M, Rorsman F, Siegbahn A, Wanders A, Carlson M. Tissue factor in ulcerative colitis, with and without concomitant primary sclerosing cholangitis. Ups J Med Sci. 2019 Nov;124(4):238-245. doi:10.1080/03009734.2019.1689209. Epub 2019 Nov 27. PubMed PMID: 31774347; PubMed Central PMCID: PMC6968534.
13. Lampinen M, Vessby J, Fredricsson A, Wanders A, Rorsman F, Carlson M. High Serum sCD40 and a Distinct Colonic T Cell Profile in Ulcerative Colitis Associated With Primary Sclerosing Cholangitis. J Crohns Colitis. 2019 Mar 26;13(3):341-350. doi: 10.1093/ecco-jcc/jjy170. PubMed PMID: 30383225.
14. Larsson JK, Dabos KJ, Höglund P, Bohr J, Münch A, Giannakou A, Nemeth A, Wurm-Johansson G, Toth E, Plevris JN, Fineron P, Koulaouzidis A, Sjöberg K. Cancer Risk in Collagenous Colitis. J Clin Med. 2019 Nov 11;8(11). pii: E1942. doi: 10.3390/jcm8111942. PubMed PMID: 31718057; PubMed Central PMCID: PMC6912303.
15. Daferera N, Hjortswang H, Ignatova S, Münch A. Single-centre experience with anti-tumour necrosis factor treatment in budesonide-refractory microscopic colitis patients. United European Gastroenterol J. 2019 Nov;7(9):1234-1240. doi: 10.1177/2050640619871750. Epub 2019 Aug 20. PubMed PMID: 31700636; PubMed Central PMCID: PMC6826524.
16. Pihl Lesnovska K, Münch A, Hjortswang H. Microscopic colitis: Struggling with an invisible, disabling disease. J Clin Nurs. 2019 Oct;28(19-20):3408-3415. doi: 10.1111/jocn.14916. Epub 2019 May 29. PubMed PMID: 31090966.
17. Christerson U, Keita ÅV, Winberg ME, Söderholm JD, Gustafson-Svärd C. Possible Involvement of Intracellular Calcium-Independent Phospholipase A(2) in the Release of Secretory Phospholipases from Mast Cells-Increased Expression in Ileal Mast Cells of Crohn’s Disease. Cells. 2019 Jul 3;8(7). pii: E672. doi:10.3390/cells8070672. PubMed PMID: 31277247; PubMed Central PMCID: PMC6678282.
18. Witt ST, Bednarska O, Keita ÅV, Icenhour A, Jones MP, Elsenbruch S, Söderholm JD, Engström M, Mayer EA, Walter S. Interactions between gut permeability and brain structure and function in health and irritable bowel syndrome. Neuroimage Clin. 2019;21:101602. doi: 10.1016/j.nicl.2018.11.012. Epub 2018 Nov 17. PubMed PMID: 30472166; PubMed Central PMCID: PMC6411611.
19. Burisch J, Zammit SC, Ellul P, Turcan S, Duricova D, Bortlik M, Andersen KW, Andersen V, Kaimakliotis IP, Fumery M, Gower-Rousseau C, Girardin G, Valpiani D, Goldis A, Brinar M, Čuković-Čavka S, Oksanen P, Collin P, Barros L, Magro F, Misra R, Arebi N, Eriksson C, Halfvarson J, Kievit HAL, Pedersen N, Kjeldsen J, Myers S, Sebastian S, Katsanos KH, Christodoulou DK, Midjord J, Nielsen KR,Kiudelis G, Kupcinskas L, Nikulina I, Belousova E, Schwartz D, Odes S, Salupere R, Carmona A, Pineda JR, Vegh Z, Lakatos PL, Langholz E, Munkholm P; Epi-IBD group. Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study. J Gastroenterol Hepatol. 2019 Jun;34(6):996-1003. doi: 10.1111/jgh.14563. Epub 2019 Jan 21. PubMed PMID:30562421.
20. Burisch J, Katsanos KH, Christodoulou DK, Barros L, Magro F, Pedersen N, Kjeldsen J, Vegh Z, Lakatos PL, Eriksson C, Halfvarson J, Fumery M, Gower-Rousseau C, Brinar M, Cukovic-Cavka S, Nikulina I, Belousova E, Myers S, Sebastian S, Kiudelis G, Kupcinskas L, Schwartz D, Odes S, Kaimakliotis IP, Valpiani D, D’Incà R, Salupere R, Chetcuti Zammit S, Ellul P, Duricova D, Bortlik M, Goldis A, Kievit HAL, Toca A, Turcan S, Midjord J, Nielsen KR, Andersen KW, Andersen V, Misra R, Arebi N, Oksanen P, Collin P, de Castro L, Hernandez V, Langholz E, Munkholm P; Epi-IBD Group. Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study. J Crohns Colitis. 2019 Feb 1;13(2):198-208. doi: 10.1093/ecco-jcc/jjy154. PubMed PMID: 30289522.
21. Eriksson C, Rundquist S, Cao Y, Montgomery S, Halfvarson J. Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. Gut. 2019 Apr;68(4):623-632. doi: 10.1136/gutjnl-2017-315521. Epub 2018 Apr 4. PubMed PMID: 29618498.
22. Eberhardson M, Hedin CRH, Carlson M, Tarnawski L, Levine YA, Olofsson PS. Towards improved control of inflammatory bowel disease. Scand J Immunol. 2019 Mar;89(3):e12745. doi: 10.1111/sji.12745. Review. PubMed PMID: 30582196.
23. Carstens A, Dicksved J, Nelson R, Lindqvist M, Andreasson A, Bohr J, Tysk C, Talley NJ, Agréus L, Engstrand L, Halfvarson J. The Gut Microbiota in Collagenous Colitis Shares Characteristics With Inflammatory Bowel Disease-Associated Dysbiosis. Clin Transl Gastroenterol. 2019 Jul;10(7):e00065. doi:10.14309/ctg.0000000000000065. PubMed PMID: 31343467; PubMed Central PMCID: PMC6708665.
24. Klingberg E, Magnusson MK, Strid H, Deminger A, Ståhl A, Sundin J, Simrén M, Carlsten H, Öhman L, Forsblad-d’Elia H. A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin. Arthritis Res Ther. 2019 Nov 27;21(1):248. doi: 10.1186/s13075-019-2018-4. PubMed PMID: 31771630; PubMed Central PMCID: PMC6880506.
25. Mavroudis G, Magnusson MK, Isaksson S, Sundin J, Simrén M, Öhman L, Strid H. Mucosal and Systemic Immune Profiles Differ During Early and Late Phases of the Disease in Patients With Active Ulcerative Colitis. J Crohns Colitis. 2019 Oct 28;13(11):1450-1458. doi: 10.1093/ecco-jcc/jjz072. PubMed PMID: 30946450.
26. Mavroudis G, Simren M, Jonefjäll B, Öhman L, Strid H. Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease. Therap Adv Gastroenterol. 2019 Feb 19;12:1756284819827689. doi: 10.1177/1756284819827689. eCollection 2019. PubMed PMID: 30815033; PubMed Central PMCID: PMC6383088.
27. Olbjørn C, Cvancarova Småstuen M, Thiis-Evensen E, Nakstad B, Vatn MH, Jahnsen J, Ricanek P, Vatn S, Moen AEF, Tannæs TM, Lindstrøm JC, Söderholm JD, Halfvarson J, Gomollón F, Casén C, Karlsson MK, Kalla R, Adams AT, Satsangi J, Perminow G. Fecal microbiota profiles in treatment-naïve pediatric inflammatory bowel disease – associations with disease phenotype, treatment, and outcome. Clin Exp Gastroenterol. 2019 Jan 31;12:37-49. doi: 10.2147/CEG.S186235. eCollection 2019. PubMed PMID: 30774408; PubMed Central PMCID: PMC6362922.
28. Amcoff K, Cao Y, Zhulina Y, Lampinen M, Halfvarson J, Carlson M. Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease. Scand J Gastroenterol. 2019 Oct;54(10):1237-1244. doi: 10.1080/00365521.2019.1670251. Epub 2019 Oct 2. PubMed PMID: 31577465.
29. Butwicka A, Olén O, Larsson H, Halfvarson J, Almqvist C, Lichtenstein P, Serlachius E, Frisén L, Ludvigsson JF. Association of Childhood-Onset Inflammatory Bowel Disease With Risk of Psychiatric Disorders and Suicide Attempt. JAMA Pediatr. 2019 Aug 19. doi: 10.1001/jamapediatrics.2019.2662. [Epubahead of print] PubMed PMID: 31424531; PubMed Central PMCID: PMC6704748.
30. Weimers P, Halfvarson J, Saunders-Pullman R, Ludvigsson JF, Peter I, Olén O, Burisch J. Inflammatory Bowel Disease and Parkinson’s Disease: A Reply to Letter to the Editor of Shih-Wei Lai. Inflamm Bowel Dis. 2019 Sep 18;25(10):e127. doi: 10.1093/ibd/izz181. PubMed PMID: 31406980.
31. Weimers P, Halfvarson J, Sachs MC, Ludvigsson JF, Peter I, Olén O, Burisch J. Association between inflammatory bowel disease and Parkinson’s disease: seek and you shall find? Gut. 2019 Jan;68(1):175-176. doi: 10.1136/gutjnl-2018-316937. Epub 2018 Jul 18. PubMed PMID: 30021791.
32. Weimers P, Halfvarson J, Sachs MC, Saunders-Pullman R, Ludvigsson JF, Peter I, Burisch J, Olén O. Inflammatory Bowel Disease and Parkinson’s Disease: A Nationwide Swedish Cohort Study. Inflamm Bowel Dis. 2019 Jan 1;25(1):111-123. doi: 10.1093/ibd/izy190. PubMed PMID: 29788069.
33. Ljungström E, Pihl Lesnovska K, Fredrikson M, Hollman Frisman G, Hjortswang H. Is QUOTE-IBD a valid questionnaire for measurement of quality of care in IBD? A validation study of the Swedish version. Scand J Gastroenterol. 2019 Oct;54(10):1245-1249. doi:10.1080/00365521.2019.1673477. Epub 2019 Oct 7. PubMed PMID: 31589082.
34. Magnusson MK, Isaksson S, Öhman L. The Anti-inflammatory Immune Regulation Induced by Butyrate Is Impaired in Inflamed Intestinal Mucosa from Patients with Ulcerative Colitis. Inflammation. 2019 Dec 3. doi: 10.1007/s10753-019-01133-8. [Epub ahead of print] PubMed PMID: 31797122.
35. Lissel M, Omidy S, Myrelid P, Block M, Angenete E. The handling of the rectal stump does not affect severe morbidity after subtotal colectomy for ulcerative colitis: a retrospective cohort study. Scand J Surg. 2019 Jun 19:1457496919857269. doi: 10.1177/1457496919857269. [Epub ahead of print] PubMedPMID: 31216958.
36. Sköldberg F, Granlund J, Discacciati A, Hjern F, Schmidt PT, Olén O. Incidence and lifetime risk of hospitalization and surgery for diverticular disease. Br J Surg. 2019 Jun;106(7):930-939. doi: 10.1002/bjs.11143. Epub 2019 Apr 23. PubMed PMID: 31012495.
37. Engström J, Lönnkvist M, Befrits R, Ljung T, Diaz-Tartera H, Holst M, Hellström PM. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy. Scand J Gastroenterol. 2019 Sep;54(9):1081-1088. doi: 10.1080/00365521.2019.1660402. Epub2019 Sep 9. PubMed PMID: 31499013.

1. Ahluwalia B, Moraes L, Magnusson MK, Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018 Apr;53(4):379-389.
2. Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, Torp J, Grip O, Nilson S, Hertervig E, Lillienau J, Marsal J. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018 Oct 11;11:1756284818801244. doi:10.1177/1756284818801244. eCollection 2018. PubMed PMID: 30344642; PubMed Central PMCID: PMC6187418.
3. Björck E, Walton Bernstedt S, Mints M, Björk J, Backman AS. Replik gällande Lynchs syndrom: – Syftet var att öka medvetenheten. Lakartidningen. 2018 May 17;115. pii: E7MI. Swedish. PubMed PMID: 29786800.
4. Bonfiglio F, Zheng T, Garcia-Etxebarria K, Hadizadeh F, Bujanda L, Bresso F, Agreus L, Andreasson A, Dlugosz A, Lindberg G, Schmidt PT, Karling P, Ohlsson B, Simren M, Walter S, Nardone G, Cuomo R, Usai-Satta P, Galeazzi F, Neri M, Portincasa P, Bellini M, Barbara G, Latiano A, Hübenthal M, Thijs V, Netea MG, Jonkers D, Chang L, Mayer EA, Wouters MM, Boeckxstaens G, Camilleri M, Franke A, Zhernakova A, D’Amato M. Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome. Gastroenterology. 2018 Jul;155(1):168-179. doi: 10.1053/j.gastro.2018.03.064. Epub 2018 Apr 5. PubMed PMID: 29626450; PubMed Central PMCID: PMC6035117.
5. Burisch J, Kiudelis G, Kupcinskas L, Kievit HAL, Andersen KW, Andersen V, Salupere R, Pedersen N, Kjeldsen J, D’Incà R, Valpiani D, Schwartz D, Odes S, Olsen J, Nielsen KR, Vegh Z, Lakatos PL, Toca A, Turcan S, Katsanos KH, Christodoulou DK, Fumery M, Gower-Rousseau C, Chetcuti Zammit S, Ellul P, Eriksson C, Halfvarson J, Magro FJ, Duricova D, Bortlik M, Fernandez A, Hernández V, Myers S, Sebastian S, Oksanen P, Collin P, Goldis A, Misra R, Arebi N, Kaimakliotis IP, Nikuina I, Belousova E, Brinar M, Cukovic-Cavka S, Langholz E, Munkholm P; Epi-IBD group. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2018 Jan 23. pii: gutjnl-2017-315568.
6. Butwicka A, Sariaslan A, Larsson H, Halfvarson J, Myrelid PE, Olén O, Frisen L, Lichtenstein P, Ludvigsson JF. No association between urbanisation, neighbourhood deprivation and IBD: a population-based study of 4 million individuals. Gut. 2019 May;68(5):947-948. doi: 10.1136/gutjnl-2018-316326. Epub 2018 Apr 24. PubMed PMID: 29691277.
7. Carstens A, Roos A, Andreasson A, Magnuson A, Agréus L, Halfvarson J, Engstrand L. Differential clustering of fecal and mucosa-associated microbiota in ’healthy’ individuals. J Dig Dis. 2018 Dec;19(12):745-752
8. Chetcuti Zammit S, Ellul P, Girardin G, Valpiani D, Nielsen KR, Olsen J, Goldis A, Lazar D, Shonová O, Nováková M, Sebastian S, Whitehead E, Carmona A, Martinez-Cadilla J, Dahlerup JF, Kievit ALH, Thorsgaard N, Katsanos KH, Christodoulou DK, Magro F, Salupere R, Pedersen N, Kjeldsen J, Carlsen K, Ioannis K, Bergemalm D, Halfvarson J, Duricova D, Bortlik M, Collin P, Oksanen P, Kiudelis G, Kupcinskas L, Kudsk K, Andersen V, O’Morain C, Bailey Y, Doron S, Shmuel O, Almer S, Arebi N, Misra R, Čuković-Čavka S, Brinar M, Munkholm P, Vegh Z, Burisch J. Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1297-1303
9. Davidson S, Sjöberg K, Engel PJH, Lo Rinc E, Fiehn AK, Vigren L, Munck LK. Microscopic colitis in Denmark and Sweden: incidence, putative risk factors, histological assessment and endoscopic activity. Scand J Gastroenterol. 2018 June;53(7):818-824.
10. Dige A, Magnusson MK, Uhrenholt C, Rasmussen TK, Kragstrup T, Öhman L, Dahlerup J, Agnholt J. Effects of Anti-TNFα Treatment on Mucosal Expression of IL-17A, IL-21, and IL-22 and Cytokine-Producing T Cell Subsets in Crohn’s Disease. Mediators Inflamm. 2018 Apr 26;2018:3279607. doi: 10.1155/2018/3279607. eCollection 2018
11. Eberhardson M, Söderling JK, Olén O. Letter: biologics treatment in Crohn’s disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors’ reply. Aliment Pharmacol Ther. 2018 Jan;47(1):147-148. doi:10.1111/apt.14398. PubMed PMID: 29226402.
12. Everhov ÅH, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, Söderling J, Ekbom A, Neovius M, Ludvigsson JF, Askling J, Olén O. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden. Gastroenterology. 2018 Feb;154(3):518-528.e15. doi:10.1053/j.gastro.2017.10.034. Epub 2017 Nov 2. PubMed PMID: 29102619.
13. Everhov ÅH, Khalili H, Askling J, Myrelid P, Ludvigsson JF, Halfvarson J, Nordenvall C, Neovius M, Söderling J, Olén O. Work Loss Before and After Diagnosis of Crohn’s Disease. Inflamm Bowel Dis. 2018 Dec 14. doi:10.1093/ibd/izy382. [Epub ahead of print] PubMed PMID: 30551185.
14. Everhov ÅH, Khalili H, Askling J, Myrelid P, Ludvigsson JF, Halfvarson J, Nordenvall C, Söderling J, Olén O, Neovius M. Sick Leave and Disability Pension in Prevalent Patients With Crohn’s Disease. J Crohns Colitis. 2018 Nov 28;12(12):1418-1428. doi: 10.1093/ecco-jcc/jjy123. PubMed PMID: 30165593.
    Everhov ÅH, Sachs MC, Malmborg P, Nordenvall C, Myrelid P, Khalili H, Elmberg M, Ekbom A, Askling J, Jakobsson G, Halfvarson J, Ludvigsson JF, Olén O. Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients. Scand J Gastroenterol. 2019 Jan;54(1):55-63. doi:10.1080/00365521.2018.1564361. Epub 2019 Jan 31. PubMed PMID: 30700170.
15. Forkel M, van Tol S, Höög C, Michaëlsson J, Almer S, Mjösberg J. Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohn’s Disease and Ulcerative Colitis. J Crohns Colitis. 2019 Jan 1;13(1):67-78. doi: 10.1093/ecco-jcc/jjy119. PubMed PMID:30496425.
16. Garcia-Etxebarria K, Zheng T, Bonfiglio F, Bujanda L, Dlugosz A, Lindberg G, Schmidt PT, Karling P, Ohlsson B, Simren M, Walter S, Nardone G, Cuomo R, Usai-Satta P, Galeazzi F, Neri M, Portincasa P, Bellini M, Barbara G, Jonkers D, Eswaran S, Chey WD, Kashyap P, Chang L, Mayer EA, Wouters MM, Boeckxstaens G, Camilleri M, Franke A, D’Amato M. Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1673-1676. doi: 10.1016/j.cgh.2018.01.047. Epub 2018 Feb 21. PubMed PMID: 29408290; PubMed Central PMCID: PMC6103908.
17. Halfvarson J, Cummings F, Grip O, Savoye G. Inflammatory bowel disease registries for collection of patient iron parameters in Europe. World J Gastroenterol. 2018 Mar 14;24(10):1063-1071
    Hedin C, Halfvarson J. Should we use vedolizumab as mono or combo therapy in ulcerative colitis? Best Pract Res Clin Gastroenterol. 2018 Feb – Apr;32-33:27-34.
18. Jonefjäll B, Simrén M, Lasson A, Öhman L, Strid H. Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis. United European Gastroenterol J. 2018 Feb;6(1):148-158. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.
19. Keita ÅV, Lindqvist CM, Öst Å, Magana CDL, Schoultz I, Halfvarson J. Gut Barrier Dysfunction-A Primary Defect in Twins with Crohn’s Disease Predominantly Caused by Genetic Predisposition. J Crohns Colitis. 2018 Nov 9;12(10):1200-1209.
20. Konya V, Czarnewski P, Forkel M, Rao A, Kokkinou E, Villablanca EJ, Almer S, Lindforss U, Friberg D, Höög C, Bergman P, Mjösberg J. Vitamin D downregulates the IL-23 receptor pathway in human mucosal group 3 innate lymphoid cells. J Allergy Clin Immunol. 2018 Jan;141(1):279-292. doi: 10.1016/j.jaci.2017.01.045. Epub 2017 Apr 20. PubMed PMID: 28433688.
21. Ludvigsson JF, Mahl M, Sachs MC, Björk J, Michaelsson K, Ekbom A, Askling J, Backman AS, Olén O. Fracture Risk in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study From 1964 to 2014. Am J Gastroenterol. 2019 Feb;114(2):291-304. doi: 10.14309/ajg.0000000000000062. PubMed PMID: 30730858.
22. Malmborg P, Mouratidou N, Sachs MC, Hammar U, Khalili H, Neovius M, Hjern A, Smedby KE, Ekbom A, Askling J, Ludvigsson JF, Olén O. Effects of Childhood-onset Inflammatory Bowel Disease on School Performance: A Nationwide Population-based Cohort Study Using Swedish Health and Educational Registers. Inflamm Bowel Dis. 2019 Mar 27. pii: izz040. doi: 10.1093/ibd/izz040. [Epub ahead of print] PubMed PMID: 30916332.
23. Miehlke S, Aust D, Mihaly E, Armerding P, Böhm G, Bonderup O, Fernández-Bañares F, Kupcinskas J, Munck LK, Rehbehn KU, Nacak T, Greinwald R, Münch A; BUG-1/LMC Study Group. Gastroenterology. 2018 Dec;155(6):1795-1804.
24. Miehlke S, Verhaegh B, Tontini GE, Madisch A, Langner C, Münch A. Microscopic colitis: pathophysiology and clinical management. Lancet Gastroenterol Hepatol. 2019 Apr;4(4):305-314
25. Nordenvall C, Olén O, Johan Nilsson P, Ekbom A, Bottai M, Myrelid P, Bergquist A. Restorative Surgery in Patients With Primary Sclerosing Cholangitis and Ulcerative Colitis Following a Colectomy. Inflamm Bowel Dis. 2018 Feb 15;24(3):624-632. doi: 10.1093/ibd/izx048. PubMed PMID: 29462381.
    Nordenvall C, Olén O, Nilsson PJ, von Seth E, Ekbom A, Bottai M, Myrelid P, Bergquist A. Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients. Aliment Pharmacol Ther. 2018 Jan;47(2):238-245. doi: 10.1111/apt.14393. Epub 2017 Oct 24. PubMed PMID: 29064110.
26. Nordenvall C, Rosvall O, Bottai M, Everhov ÅH, Malmborg P, Smedby KE, Ekbom A, Askling J, Ludvigsson JF, Myrelid P, Olén O. Surgical Treatment in Childhood-onset Inflammatory Bowel Disease-A Nationwide Register-based Study of 4695 Incident Patients in Sweden 2002-2014. J Crohns Colitis. 2018 Jan 24;12(2):157-166. doi: 10.1093/ecco-jcc/jjx132. PubMed PMID: 29029152.
27. Olén O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, Ekbom A, Malmborg P, Ludvigsson JF. Increased Mortality of Patients With Childhood-Onset Inflammatory Bowel Diseases, Compared With the General Population. Gastroenterology. 2019 Feb;156(3):614-622. doi: 10.1053/j.gastro.2018.10.028. Epub 2018 Oct 17. PubMed PMID: 30342031.
28. Olén O, Stephansson O, Backman AS, Törnblom H, Simrén M, Altman M. Pre- and perinatal stress and irritable bowel syndrome in young adults – A nationwide register-based cohort study. Neurogastroenterol Motil. 2018 Nov;30(11):e13436. doi: 10.1111/nmo.13436. Epub 2018 Aug 7. PubMed PMID: 30084125.
29. Rolandsdotter H, Eberhardson M, Fagerberg UL, Finkel Y. Granulocyte and Monocyte Apheresis for Induction of Remission in Children With New Onset Inflammatory Bowel Colitis. J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):84-89
30. Rolandsdotter H, Jönsson-Videsäter K, L Fagerberg U, Eberhardson M, Finkel Y. Mucosal Cytokine Profiles After Induction Therapy With Granulocyte/Monocyte Apheresis in New-onset Inflammatory Colitis. J Pediatr Gastroenterol Nutr. 2018 Apr;66(4):e103-e107.
31. Rundquist S, Eriksson C, Nilsson L, Angelison L, Jäghult S, Björk J, Grip O, Hjortswang H, Strid H, Karlén P, Montgomery S, Halfvarson J. Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 2018 Oct – Nov;53(10-11):1257-1263. doi: 10.1080/00365521.2018.1519597. Epub 2018 Oct 24. PMID:30353751
32. Sköldberg F, Olén O, Ekbom A, Schmidt PT. Appendectomy and Risk of Subsequent Diverticular Disease Requiring Hospitalization: A Population-Based Case-Control Study. Dis Colon Rectum. 2018 Jul;61(7):830-839. doi:10.1097/DCR.0000000000001086. PubMed PMID: 29878951.
33. Svensson M, Bergman D, Olén O, Myrelid P, Bohr J, Wickbom A, Khalili H, Münch A, Halfvarson J, Ludvigsson JF. Validating microscopic colitis (MC) in Swedish pathology registers. Scand J Gastroenterol. 2018 Dec;53(12):1469-1475. doi: 10.1080/00365521.2018.1543446. Epub 2019 Jan 2. PMID:30600733
34. Uusijärvi A, Olén O, Malmborg P, Eriksson M, Grimheden P, Arnell H. Combining Rome III criteria with alarm symptoms provides high specificity but low sensitivity for functional gastrointestinal disorders in children. Acta Paediatr. 2018 Feb 27. doi: 10.1111/apa.14297. [Epub ahead of print] PubMed PMID: 29486063.
35. Walton Bernstedt S, Björk J, Mints M, Björck E, Backman AS. [<p>Lynch syndrome is a major cause of monogenetic familial colorectal cancer</p>]. Lakartidningen. 2018 Apr 16;115. pii: EY3C. Review. Swedish. PubMed PMID:29664536.
36. Weimers P, Halfvarson J, Sachs MC, Ludvigsson JF, Peter I, Olén O, Burisch J. Association between inflammatory bowel disease and Parkinson’s disease: seek and you shall find? Gut. 2019 Jan;68(1):175-176. doi: 10.1136/gutjnl-2018-316937. Epub 2018 Jul 18. PubMed PMID: 30021791.
37. Weimers P, Halfvarson J, Sachs MC, Saunders-Pullman R, Ludvigsson JF, Peter I, Burisch J, Olén O. Inflammatory Bowel Disease and Parkinson’s Disease: A Nationwide Swedish Cohort Study. Inflamm Bowel Dis. 2019 Jan 1;25(1):111-123. doi: 10.1093/ibd/izy190. PubMed PMID: 29788069.
38. Wickbom A, Bohr J, Nyhlin N, Eriksson A, Lapidus A, Münch A, Ung KA, Vigren L, Öst Å, Tysk C; Swedish Organisation for the Study of Inflammatory Bowel Disease (SOIBD). Microscopic colitis in patients with ulcerative colitis or Crohn’s disease: a retrospective observational study and review of the literature. Scand J Gastroenterol. 2018 Apr;53(4):410-416. doi:10.1080/00365521.2018.1430252. Epub 2018 Mar 16. PubMed PMID: 29546806.
39. Wintzell V, Svanström H, Olén O, Melbye M, Ludvigsson JF, Pasternak B. Association between use of azathioprine and risk of acute pancreatitis in children with inflammatory bowel disease: a Swedish-Danish nationwide cohort study. Lancet Child Adolesc Health. 2019 Mar;3(3):158-165. doi:10.1016/S2352-4642(18)30401-2. Epub 2019 Jan 24. PubMed PMID: 30685366.
40. Worley G, Nordenvall C, Askari A, Pinkney T, Burns E, Akbar A, Olén O, Ekbom A, Bottai M, Myrelid P, Faiz O. Restorative surgery after colectomy for ulcerative colitis in England and Sweden: observations from a comparison of nationwide cohorts. Colorectal Dis. 2018 Sep;20(9):804-812. doi:10.1111/codi.14113. Epub 2018 Apr 19. PubMed PMID: 29603863.
41. Yakymenko O, Schoultz I, Gullberg E, Ström M, Almer S, Wallon C, Wang A, Keita ÅV, Campbell BJ, McKay DM, Söderholm JD. Infliximab restores colonic barrier to adherent-invasive E. coli in Crohn’s disease via effects on epithelial lipid rafts. Scand J Gastroenterol. 2018 Jun;53(6):677-684. doi: 10.1080/00365521.2018.1458146. Epub 2018 Apr 24. PMID:29688802

1. Ludvigsson JF, Büsch K, Olén O, Askling J, Smedby KE, Ekbom A, Lindberg E, Neovius M. Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study. BMC Gastroenterol. 2017 Jan 31;17(1):23.
2. Halfvarson J, Brislaw CJ, Lamendella R, Vázquez-Baeza Y, Walters WA, Bramer LM, D’Amato M, Bonfiglio F, McDonald D, Gonzalez A, McClure EE, Dunklebarger MF, Knight R, Jansson JK. Dynamics of the human gut microbiome in Inflammatory Bowel Disease. Nat Microbiol. 2017 Feb 13;2:17004.
3. Angelison L, Almer S, Eriksson A, Karling P, Fagerberg U, Halfvarson J, Marsal J, Thörn M, Björk J, Hindorf U, Löfberg R, Bajork A, Hjortswang H, Hammarlund P, Grip O, Torp J, Hertervig E. Long-term outcome of infliximab treatment in chronic active ulcerative colitis: A Swedish multicentre study of 250 patients. Aliment Pharmacol Ther. 2017 Feb;45(4):519-532.
4. L. Jakobsson G, Sternegård E, Olén O, Myrelid P, Ljung R, Strid H, Halfvarson J, F. Ludvigsson J. Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG). Scand J Gastroenterol. 2017 Feb;52(2):216-221.
5. Klingberg K, Strid H, Stahl A, Deminger A, Carlsten H, Öhman L, Forsblad-d’Elia HA longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther. 2017 Feb 2;19(1):21
6. Olén O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, Ekbom A, Malmborg P, Ludvigsson JF. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ. 2017 Sep 20;358:j3951.
7. Amcoff K, Stridsberg M, Lampinen M, Magnuson A, Carlson M, Halfvarson J. Clinical implications of assay specific differences in f-Calprotectin when monitoring inflammatory bowel disease activity over time. Scand J Gastroenterol. 2017 Mar;52(3):344-350.
8. Westerlind H, Mellander MR, Bresso F, Munch A, Assadi G, Hübenthal M, Lieb W, Källberg H, Brynedal B, Padyukov L, Halfvarson J, Törkvist L, Andreasson A, Agreus L, Almer S, Miehlke S, Madisch A, Ohlsson B, Löfberg R, Hultcranz R, Franke A, D’Amato M. Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis. Gut. 2017 Mar;66 (3):421-428
9. Bergemalm D, Kruse R, Sapnara M, Halfvarson J, Hultgren Hörnquist E. Elevated fecal peptidase D at onset of colitis in Gαi2 -/- mice, a mouse model of IBD. PLoSOne 2017 Mar 21;12(3):e0174275.
   Angelison L, Marsal J, Hertervig E. Letter: how to define remission in ulcerative colitis – histological remission should be considered. Authors’ reply. Aliment Pharmacol Ther. 2017 Apr;45(8):1177-1178.
   Konya V, Czarnewski P, Forkel M, Rao A, Kokkinou E, Villablanca EJ, Almer S, Lindforss U, Friberg D, Höög C, Bergman P, Mjösberg J. Vitamin D downregulates the IL-23 receptor pathway in human mucosal group 3 innate lymphoid cells. J Allergy Clin Immunol. 2018 Jan;141(1):279-292. Epub 2017 Apr 20.
10. Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, Carneiro A, Marsal J. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017 May;66(5):581-592
11. Nyberg L, Björk J, Björkdahl P, Ekberg O, Sjöberg K, Vigren L. Sclerosing mesenteritis and mesenteric panniculitis – clinical experience and radiological features. BMC Gastroenterol. 2017 Jun 13;17(1):75.
12. Magnusson MK, Strid H, Isaksson S, Simrén M and Öhman L. The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis. Inflamm Bowel Dis. 2017 Jun;23(6):956-966
13. Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, Karling P, Söderman C, The SWIBREG Vedolizumab Study Group, Myrelid P, Cao Y, Sjöberg D, Thörn M, Karlén P, Hertervig, E, Strid H, Ludvigsson JF, Almer S, Halfvarson J. Long-term effectiveness of vedolizumab in inflammatory bowel disease: A national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG) Scand J Gastroenterol. 2017 Jun – Jul;52(6-7):722-729
14. Huang H, Fang M, Jostins L, Umićević Mirkov M, Boucher G, Anderson C A, Andersen V, Cleynen I, Cortes A, Crins F, D’Amato M, Deffontaine V, Dimitrieva J, Docampo E, Elansary M, Kai-How Farh K, Franke A, Gori A-S, Goyette P, Halfvarson J, Haritunians T, Knight J, Lawrence IC, Lees CW, Louis E, Mariman R, Meuwissen T, Mni M, Momozawa Y, Parkes M, Spain SL, Théâtre E, Trynka G, Satsangi J, van Sommeren S, Vermeire S, Xavier RJ, International IBD Genetics Consortium, Weersma RK, Duerr RH, Mathew CG, Rioux JD, McGovern D PB, Cho JH, Georges M, Daly MJ, Barrett JC. Association mapping of inflammatory bowel disease loci to single variant resolution. Nature. 2017 Jul 13;547(7662):173-178.
15. Eberhardson M, Söderling JK, Neovius M, Cars T, Myrelid P, Ludvigsson JF, Askling J, Ekbom A, Olén O. Anti-TNF treatment in Crohn’s disease and risk of bowel resection-a population based cohort study. Aliment Pharmacol Ther. 2017 Sep;46(6):589-598.
16. Burisch, J, Vegh Z, Katsanos K, Christodoulou D, Lazar D, Goldis A, O’Morain C, Fernandez A, Pereira S, Myers S, Sebastian S, Pedersen N, Olsen J, Nielsen K R, Schwartz D, Odes S, Almer S, Halfvarson J, Turk N, Cukovic-Cavka S, Nikulina I, Belousova E, Duricova D, Shonová O, Salupere R, Barros L, Magro F, Jonaitis L, Kupcinskas L, Turcan S, Kaimakliotis I, Ladefoged K, Kudsk K, Andersen V, Vind I, Thorsgaard N, Oksanen P, Collin P, Dal Piaz G, Santini A, Niewiadomski O, Bell S, Moum B, Arebi N, Kjeldsen J, Carlsen K, Langholz E, Lakatos P L, Munkholm P, Gerdes LU, Dahlerup, J F for the EpiCom study group.Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort – An ECCO-EpiCom study J Crohns Colitis. 2017 Oct 1;11(10):1213-1222
17. Günaltay S, Repsilber D, Helenius G, Nyhlin N, Bohr J, Hultgren O, Hultgren Hörnquist E. Oligoclonal T-cell Receptor Repertoire in Colonic Biopsies of Patients with Microscopic Colitis and Ulcerative Colitis. Inflamm Bowel Dis. 2017
18. Wickbom A, Nyhlin N, Montgomery SM, Bohr J, Tysk C Family history, comorbidity, smoking and other risk factors in microscopic colitis: a case-control study.. Eur J Gastroenterol Hepatol. 2017
19. Günaltay S, Rademacher L, Hultgren Hörnquist E, Bohr J. Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis. World J Gastroenterol. 2017

1. Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., and Marsal, J. Vedolizumab treatment for immune checkpoint inhibitor induced enterocolitis. Cancer Immunol. Immunother. [Springer] (Accepted)
2. Marsal J, Hertervig E. Introduktion av biosimilarer kräver noggrann övervakning. Lakartidningen. 2016 Mar 3;113.
3. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: A randomised, placebo-controlled 12-month trial. Münch A, Bohr J, Benoni C, Miehlke S, Olesen M, Öst A, Strandberg L, Hellström PM, Hertervig E, Armerding P, Stehlik J, Lindberg G, Björk J, Lapidus A, Löfberg R, Bonderup O, Avnström S, Rössle M, Dilger K, Mueller R, Greinwald R, Tysk C, Ström M. Gut 2016;65:47–56.
4. A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn’s Disease and Human Gut Microbiome Composition. Li D, Achkar JP, Haritunians T, Jacobs JP, Hui KY, D’Amato M, Brand S, Radford-Smith G, Halfvarson J, Niess JH, Kugathasan S, Büning C, Schumm LP, Klei L, Ananthakrishnan A, Aumais G, Baidoo L, Dubinsky M, Fiocchi C, Glas J, Milgrom R, Proctor DD, Regueiro M, Simms LA, Stempak JM, Targan SR, Törkvist L, Sharma Y, Devlin B, Borneman J, Hakonarson H, Xavier RJ, Daly M, Brant SR, Rioux JD, Silverberg MS, Cho JH, Braun J, McGovern DP, Duerr RH. Gastroenterology. 2016 Oct;151(4):724-32
5. Rivas MA, Graham D, Sulem P, Stevens C, Desch AN, Goyette P, Gudbjartsson D, Jonsdottir I, Thorsteinsdottir U, Degenhardt F, Mucha S, Kurki MI, Li D, D’Amato M, Annese V, Vermeire S, We- ersma RK, Halfvarson J, Paavola-Sakki P, Lappalainen M, Lek M, Cummings B, Tukiainen T, Hari- tunians T, Halme L, Koskinen LL, Ananthakrishnan AN, Luo Y, Heap GA, Visschedijk MC; UK IBD Genetics Consortium; NIDDK IBD Genetics Consortium, MacArthur DG, Neale BM, Ahmad T, Ander- son CA, Brant SR, Duerr RH, Silverberg MS, Cho JH, Palotie A, Saavalainen P, Kontula K, Färkkilä M, McGovern DP, Franke A, Stefansson K, Rioux JD, Xavier RJ, Daly MJ, Barrett J, de Lane K, Ed- wards C, Hart A, Hawkey C, Jostins L, Kennedy N, Lamb C, Lee J, Lees C, Mansfield J, Mathew C, Mowatt C, Newman B, Nimmo E, Parkes M, Pollard M, Prescott N, Randall J, Rice D, Satsangi J, Simmons A, Tremelling M, Uhlig H, Wilson D, Abraham C, Achkar JP, Bitton A, Boucher G, Croitoru K, Fleshner P, Glas J, Kugathasan S, Limbergen JV, Milgrom R, Proctor D, Regueiro M, Schumm PL, Sharma Y, Stempak JM, Targan SR, Wang MH. A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. Nat Commun. 2016 Aug 9;7:12342
6. LACC1 polymorphisms in inflammatory bowel disease and juvenile idiopathic arthritis. Assadi G, Saleh R, Hadizadeh F, Vesterlund L, Bonfiglio F, Halfvarson J, Törkvist L, Eriksson AS, Harris HE, Sundberg E, D’Amato M. Genes Immun. 2016 Jun;17(4):261-4.
7. Assadi G, Vesterlund L, Bonfiglio F, Mazzurana L, Cordeddu L, Schepis D, Mjösberg J, Sabrina Ruhrmann; Alessia Fabbri; Vladana Vukojevic; Piergiorgio Percipalle; Florian Albert Salomons; Jurga Laurencikiene; Leif Törkvist; Jonas Halfvarson; Mauro D’Amato. Functional analyses of the Crohn’s disease risk gene LACC1″. PLoS One. 2016 Dec 13;11(12):e0168276
8. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, Park YR, Raychaudhuri S, Pouget JG, Hübenthal M, Folseraas T, Wang Y, Esko T, Metspalu A, Westra HJ, Franke L, Pers TH, Weersma RK, Collij V, D’Amato M, Halfvarson J, Jensen AB, Lieb W, Degenhardt F, Forstner AJ, Hofmann A; International IBD Genetics Consortium (IIBDGC); International Genetics of Ankylosing Spondylitis Consortium (IGAS); International PSC Study Group (IPSCSG); Genetic Analysis of Psoriasis Consortium (GAPC); Psoriasis Association Genetics Extension (PAGE), Schreiber S, Mrowietz U, Juran BD, Lazaridis KN, Brunak S, Dale AM, Trembath RC, Weidinger S, Weichenthal M, Ellinghaus E, Elder JT, Barker JN, Andreassen OA, McGovern DP, Karlsen TH, Barrett JC, Parkes M, Brown MA, Franke A. Nat Genet. 2016 May;48(5):510-8. doi: 10.1038/ng.3528. Epub 2016 Mar 14.
9. HLA Associations Distinguish Collagenous From Lymphocytic Colitis.
   Westerlind H, Bonfiglio F, Mellander MR, Hìbenthal M, Brynedal B, Björk J, Törkvist L, Padyukov L, Ohlsson B, Löfberg R, Hultcrantz R, Franke A, Bresso F, D’Amato M. Am J Gastroenterol. 2016 Aug;111(8):1211-3. doi: 10.1038/ajg.2016.215. No abstract available.
10. Microscopic colitis: a descriptive clinical cohort study of 795 patients with collagenous and lymphocytic colitis. Mellander MR, Ekbom A, Hultcrantz R, Löfberg R, Öst Å, Björk J. Scand J Gastroenterol. 2016;51(5):556-62. doi: 10.3109/00365521.2015.112428
11. Elevated fecal levels of eosinophil granule proteins predict collagenous colitis in patients referred to colonoscopy due to chronic non-bloody diarrhea.Wagner M, Sjöberg K, Vigren L, Olesen M, Benoni C, Toth E, Carlson M. Scand J Gastroenterol. 2016 Jul;51(7):835-41. doi: 10.3109/00365521.2016.1141432.
12. Smoking Status Influences Clinical Outcome in Collagenous Colitis. Münch A, Tysk C, Bohr J, Madisch A, Bonderup OK, Mohrbacher R, Mueller R, Greinwald R, Ström M, Miehlke S. J Crohns Colitis. 2016 Apr;10(4):449-54. doi: 10.1093/ecco-jcc/jjv235.PMID:26721941
13. Concordance in Anti-OmpC and Anti-I2 Indicate the Influence of Genetic Predisposition: Results of a European Study of Twins with Crohn’s Disease. Amcoff K, Joossens M, Pierik MJ, Jonkers D, Bohr J, Joossens S, Romberg-Camps M, Nyhlin N, Wickbom A, Rutgeerts PJ, Tysk C, Bodin L, Colombel JF, Vermeire S, Halfvarson J. J Crohns Colitis. 2016 Jun;10(6):695-702. doi: 10.1093/ecco-jcc/jjw021
14. Zhulina Y, Udumyan R, Tysk C, Montgomery S, Halfvarson J. The changing face of Crohn’s disease: a population-based study of the natural history of Crohn’s disease in Örebro, Sweden 1963-2005. Scand J Gastroenterol. 2016 Mar;51(3):304-13.
15. Development of an index to define overall disease severity in IBD. Siegel CA, Whitman CB, Spiegel BM, Feagan B, Sands B, Loftus EV Jr, Panaccione R, D’Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O’Morain C, Lakatos PL, McGovern DP, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. Gut. 2016 Oct 25. pii: gutjnl-2016-312648. doi: 10.1136/gutjnl-2016-312648.
16. Use of complementary and alternative medicine in Swedish patients with inflammatory bowel disease: a controlled study. Oxelmark L, Lindberg A, Löfberg R, Sternby B, Eriksson A, Almer S, Befrits R, Fossum B, Karlén P, Broström O, Tysk C; SOIBD, the Swedish Organization for the study of Inflammatory Bowel Disease.Eur J Gastroenterol Hepatol. 2016 Nov;28(11):1320-8. doi: 10.1097/MEG.0000000000000710.
17. Nordenvall C, Olén O, Nilsson PJ, Ekbom A, Bottai M, Myrelid P. The fate of reconstructive surgery following colectomy for inflammatory bowel disease in Sweden: A population-based cohort study. Journal of Crohn’s and Colitis 2016, accepted 29 February.
18. Khalili H, Granath F, Smedby KE, Ekbom A, Neovius M, Chan AT, Olén O. Association Between Long-term Oral Contraceptive Use and Risk of Crohn’s Disease Complications in a Nationwide Study. Gastroenterology 2016;150:1561–1567.
19. Khalili, Eriksson, Neovius, Ekbom, Ludvigsson, Askling, Chan, Olén. Oral Contraceptive Use and Risk of Ulcerative Colitis Progression: A Nationwide Study. American Journal of Gastroenterology 2016, accepted Aug 30.
20. Ludvigsson JF, Büsch K, Olén O, Askling J, Smedby KE, Ekbom A, Lindberg E, Neovius M. Prevalence of Paediatric Inflammatory Bowel Disease in Sweden: a Nationwide Population-Based Register Study. BMC Gastroenterology, conditionally accepted 23 June 2016.
21. Jakobsson GL, Sternegård E, Olén O, Myrelid P, Ljung R, Strid H, Halfvarson J, Ludvigsson JF. Validating inflammatory bowel disease in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG). Scandinavian Journal of Gastroenterology, accepted 5 October 2016.